Anti-PD-L2 antibody [CAL28]
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(3 Publications)
Rabbit Recombinant Monoclonal PD-L2 antibody. Suitable for IP, WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 3 publications.
View Alternative Names
CD273, B7DC, PDCD1L2, PDL2, PDCD1LG2, Programmed cell death 1 ligand 2, PD-1 ligand 2, PD-L2, PDCD1 ligand 2, Programmed death ligand 2, Butyrophilin B7-DC, B7-DC
- Flow Cyt (Intra)
Supplier Data
Flow Cytometry (Intracellular) - Anti-PD-L2 antibody [CAL28] (AB256386)
Intracellular flow cytometric analysis of 4% paraformaldehyde-fixed, 90% methanol-permeabilized HDLM-2 (human Hodgkin lymphoma) cells labeling PD-L2 with ab256386 at 1/500 dilution (Red) compared with a Rabbit monoclonal IgG Isotype control (ab172730) (Black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue). Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077), at 1/2000 dilution was used as the secondary antibody.
- IP
Supplier Data
Immunoprecipitation - Anti-PD-L2 antibody [CAL28] (AB256386)
PD-L2 was immunoprecipitated from 0.35 mg of HDLM-2 (human Hodgkin lymphoma) whole cell lysate with ab256386 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab256386X at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used as secondary antibody at 1/5000 dilution.
Lane 1 : HDLM-2 whole cell lysate 10 μ (Input).
Lane 2 : ab256386 IP in HDML-2 whole cell lysate.
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab256386 in HDML-2 whole cell lysate.
Blocking and dilution buffer and concentration : 5% NFDM/TBST.
Exposure time : 5 seconds.
All lanes:
Immunoprecipitation - Anti-PD-L2 antibody [CAL28] (ab256386)
Predicted band size: 31 kDa
Observed band size: 45-60 kDa
false
- WB
Supplier Data
Western blot - Anti-PD-L2 antibody [CAL28] (AB256386)
Blocking and dilution buffer : 5% NFDM/TBST.
Exposure time : 10 seconds.
Negative control : Jurkat. (PMID : 27631416).
All lanes:
Western blot - Anti-PD-L2 antibody [CAL28] (ab256386) at 1/1000 dilution
Lane 1:
HDLM-2 (human Hodgkin lymphoma) whole cell lysate at 20 µg
Lane 2:
Jurkat (human T cell leukemia cell line from peripheral blood) whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 31 kDa
Observed band size: 45-60 kDa
false
- WB
Supplier Data
Western blot - Anti-PD-L2 antibody [CAL28] (AB256386)
Blocking and dilution buffer : 5% NFDM/TBST.
Exposure time : 3 minutes.
All lanes:
Western blot - Anti-PD-L2 antibody [CAL28] (ab256386) at 1/1000 dilution
Lane 1:
MDA-MB-231 (human breast adenocarcinoma cell line) whole cell lysate at 20 µg
Lane 2:
U-2 OS (human bone osteosarcoma epithelial cell line) whole cell lysate at 20 µg
Lane 3:
MG-63 (human osteosarcoma fibroblast) whole cell lysate at 20 µg
Lane 4:
Saos-2 (human osteosarcoma cell line) whole cell lysate at 20 µg
Lane 5:
Human tonsil lysate at 20 µg
Lane 6:
Human lung lysate at 20 µg
Lane 7:
Human lung cancer lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 31 kDa
Observed band size: 45-60 kDa
false
Related conjugates and formulations (8)
-
Anti-PD-L2 antibody [CAL28] - BSA and Azide free
-
578 PE
PE Anti-PD-L2 antibody [CAL28]
-
660 APC
APC Anti-PD-L2 antibody [CAL28]
-
519 Alexa Fluor® 488
Alexa Fluor® 488 Anti-PD-L2 antibody [CAL28]
-
665 Alexa Fluor® 647
Alexa Fluor® 647 Anti-PD-L2 antibody [CAL28]
-
617 Alexa Fluor® 594
Alexa Fluor® 594 Anti-PD-L2 antibody [CAL28]
-
603 Alexa Fluor® 568
Alexa Fluor® 568 Anti-PD-L2 antibody [CAL28]
-
565 Alexa Fluor® 555
Alexa Fluor® 555 Anti-PD-L2 antibody [CAL28]
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
PD-L2 offers protection to tissues from autoimmunity by regulating T-cell activation and fostering tolerance. By engaging with its receptor PD-1 PD-L2 forms a complex that modulates the immune response to prevent overactivation. This interaction limits the immune system's potential damage to healthy tissues maintaining proper immune function in diverse environments.
Pathways
PD-L2 participates in the immune checkpoint pathways where it works closely with PD-1 to mediate immune responses. PD-L2 forms an important part of the program death-1 (PD-1) pathway which plays a prominent role in downregulating T-cell activity. It relates to proteins such as PD-L1 which also interacts with PD-1 modulating immune tolerance and response to infections or tumors.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (3)
Recent publications for all applications. Explore the full list and refine your search
Molecular medicine (Cambridge, Mass.) 30:229 PubMed39580381
2024
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 23: PubMed35008490
2021
Applications
Unspecified application
Species
Unspecified reactive species
OncoTargets and therapy 12:10099-10105 PubMed31819504
2019
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com